Considering Phase I (US) trial for BGB-11417 - CLL Support
Considering Phase I (US) trial for BGB-11417
You need to be a member of this community to see this post.
Read more about...
22 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
Clinical Trial with BGB-11417
Hi all!
Would love to hear from anyone who is participating in / has considered and/or has...
2nd gen BCL-2 inhibitor in trials and looking promising -- Sonrotoclax (BGB-11417)
https://www.beigenemedical.com/CongressDocuments/Tam_BGB-11417-101_ASH_Presentation_2023.pdf
This...
A cautionary tale about using AI
[EDIT: I've purposely left this post Public so that other internet users can find it.]
I...
Pirtobrutinib Delays Progression in CLL Already Treated With a BTK Inhibitor. (BRUIN CLL-321 Phase III trial results reported at ASH2024)
Pirtobrutinib is the first FDA approved non-covalent BTK inhibitor (BTKi) for the treatment of CLL....
YABTKi or Yet Another BTK inhibitor - an A to Z list of Bruton's Tyrosine Kinase Inhibitors and Degraders following ibrutinib's success
I'll admit that YABTKi is not a recognised CLL related acronym, (acronym lists are here...
Related Posts
Zanubrutinib looks promising on all fronts in first interim analysis of ALPINE Trial - Ibrutinib v Zanubrutinib in R/R CLL - report from EHA
CLL Treatment concerns 
BTK inhibitors for the treatment of CLL - the current state of play of 'brutinibs'- Venetoclax plus obinutuzumab - the first chemotherapy-free, fixed-duration first line CLL treatment approved by Health Canada
- BRUIN Study: phase 1/2 study of Pirtobrutinib (formerly Loxo 305) in relapsed or refractory B-cell malignancies
